dexmedetomidine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D | 1 |
1 other study(ies) available for dexmedetomidine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Astrocytes; Dexmedetomidine; Disease Models, Animal; Dopaminergic Neurons; Interleukin-6; Mice; Mice, Inbred C57BL; NF-kappa B; Pain; Parkinson Disease; Quality of Life; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2022 |